Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome

Stafford, Lesley; Judd, Fiona; Gibson, Penny; Komiti, Angela; Mann, G. Bruce; Quinn, Michael

doi:10.1007/s00520-014-2571-y

Cited by 61 publications

(43 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another reported that having received treatment for anxiety or depression before diagnosis of breast or gynaecological cancer predicted depression 12 months later but not anxiety. However, this variable predicted neither outcome at 18‐ nor 24‐month follow‐up . In the same study, being in treatment for anxiety or depression at the time of diagnosis predicted anxiety 12 and 18 months later and depression at 18 months, but neither outcome at 2 years .…”

Section: Resultsmentioning

confidence: 89%

“…However, this variable predicted neither outcome at 18‐ nor 24‐month follow‐up . In the same study, being in treatment for anxiety or depression at the time of diagnosis predicted anxiety 12 and 18 months later and depression at 18 months, but neither outcome at 2 years . The third paper to find an effect of distress assessed at baseline reported that premorbid psychiatric history (diagnoses unspecified) predicted severe trauma 15 months after surgery for breast cancer .…”

Section: Resultsmentioning

confidence: 93%

“…Four papers (4 studies) used different measures of distress at baseline and follow‐up. Three found positive effects.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Predictors of emotional distress a year or more after diagnosis of cancer: A systematic review of the literature

et al. 2018

View full text Add to dashboard Cite

ObjectiveWhy some people recover emotionally after diagnosis and treatment of cancer and others do not is poorly understood. To identify factors around the time of diagnosis that predict longer‐term distress is a necessary step in developing interventions to reduce patients' vulnerability. This review identified the demographic, clinical, social, and psychological factors available at or within 3 months of diagnosis that are reliable predictors of emotional distress at least 12 months later.MethodsA systematic search of literature for prospective studies addressing our research question and predicting a range of distress outcomes was conducted. Thirty‐nine papers (reporting 36 studies) were subjected to narrative synthesis of the evidence.ResultsThere was no consistent evidence that demographic, clinical, or social factors reliably predicted longer‐term distress. Of the psychological factors examined, only baseline distress (significant in 26 of 30 relevant papers; 24 of 28 studies) and neuroticism (significant in all 5 papers/studies that examined it) consistently predicted longer‐term distress. The heterogeneity of included studies, particularly in populations studied and methodology, precluded meta‐analytic techniques.ConclusionsThis review supports current clinical guidance advising early assessment of distress as a marker of vulnerability to persistent problems. Additionally, neuroticism is also indicated as a useful marker of vulnerability. However, the review also highlights that more sophisticated research designs, capable of identifying the psychological processes that underlie the association between these marker variables and persistent distress, are needed before more effective early interventions can be developed.

show abstract

Section: Resultsmentioning

confidence: 89%

Section: Resultsmentioning

confidence: 93%

See 1 more Smart Citation

Predictors of emotional distress a year or more after diagnosis of cancer: A systematic review of the literature

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Doxorubicin, cyclophosphamide, and the combination of doxorubicin and cyclophosphamide did not alter locomotor activity relative to saline treatment [F (3,20)=0.32, P=0.81] (Fig. 2).…”

Section: Doxorubicin and Cyclophosphamide Do Not Affect Locomotor Actmentioning

confidence: 85%

“…This incidence rate of cancer patients is higher than the prevalence in the community (3-4%) [2]. Furthermore, the prevalence rate of anxiety is 18.1% in breast or gynaecologic cancer patients [3]. Wittmann et al reported that the rates of anxiety and depression were 20.5% and 16.8%, respectively [4].…”

Section: Introductionmentioning

confidence: 97%

Doxorubicin and cyclophosphamide treatment produces anxiety-like behavior and spatial cognition impairment in rats: Possible involvement of hippocampal neurogenesis via brain-derived neurotrophic factor and cyclin D1 regulation

Kitamura

Hattori

Yoneda

et al. 2015

Behavioural Brain Research

View full text Add to dashboard Cite

Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events

Peng,

Wang,

Sun

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

ObjectiveDrug‐induced side effects, particularly serious adverse events (SAEs), often affect cancer patients enrolled in clinical trials. However, little is known about anxiety and depression in cancer patients who experienced SAEs. This study evaluated the prevalence of anxiety and depression in cancer patients enrolled in clinical trials who experienced SAEs and explored the risk factors.MethodsA multi‐center, cross‐sectional survey was conducted in hospitals affiliated with the University of Science and Technology of China from December 2021 to November 2022. A total of 112 cancer patients who experienced SAEs while enrolled in clinical trials, and who completed the informed consent process and study questionnaires, were included in the final analysis.ResultsThe rate of moderate–severe depression in cancer patients was 38.4% and that of moderate–severe anxiety was 13.4%. Among the patients who had moderate–severe anxiety, 93.3% had concurrent moderate–severe depression. Lower cognitive function and lower global quality of life were risk factors for depression in cancer patients who experienced SAEs. Pain, low emotional function, low global quality of life, and a high Impact of Events Scale score were risk factors for anxiety.ConclusionsCancer patients enrolled in a clinical trial who experienced SAEs tended to be anxious and depressed, particularly the latter. These results indicate the need to evaluate anxiety and depression, and mental health treatment among cancer patients with SAEs in clinical trials.

show abstract

Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome

Cited by 61 publications

References 42 publications

Predictors of emotional distress a year or more after diagnosis of cancer: A systematic review of the literature

Predictors of emotional distress a year or more after diagnosis of cancer: A systematic review of the literature

Doxorubicin and cyclophosphamide treatment produces anxiety-like behavior and spatial cognition impairment in rats: Possible involvement of hippocampal neurogenesis via brain-derived neurotrophic factor and cyclin D1 regulation

Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events

Contact Info

Product

Resources

About